Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print August 10, 2005, doi:10.1212/01.wnl.0000174472.03292.dd)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
01.wnl.0000174472.03292.ddv1
65/6/820    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veldink, J. H.
Right arrow Articles by Van den Berg, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veldink, J. H.
Right arrow Articles by Van den Berg, L. H.
NEUROLOGY 2005;65:820-825
© 2005 American Academy of Neurology

SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS

J. H. Veldink, MD, PhD, S. Kalmijn, MD, PhD, A. H. Van der Hout, MD, PhD, H. H. Lemmink, MD, PhD, G. J. Groeneveld, MD, PhD, C. Lummen, H. Scheffer, MD, PhD, J.H.J. Wokke, MD, PhD and L. H. Van den Berg, MD, PhD

From the Department of Neurology (Drs. Veldink, Kalmijn, Groeneveld, Wokke, Van den Berg), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht; the Department of Clinical Genetics (Drs. Van der Hout and Lemmink, C. Lummen), University Hospital Groningen; and the Department of Medical Genetics (Dr. Scheffer), University Hospital St. Radboud, Nijmegen, The Netherlands.

address correspondence and reprint requests to Dr. Leonard H. van den Berg, Department of Neurology, G.03.228, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands; e-mail: l.h.vandenberg{at}neuro.azu.nl

Background: ALS is believed to be multifactorial in origin with modifying genes affecting its clinical expression. Childhood-onset spinal muscular atrophy (SMA) is an autosomal recessive disorder of motor neurons, caused by mutations of the survival motor neuron (SMN) gene. The SMN gene exists in two highly homologous variants: SMN1, the causative gene responsible for the production of the majority of functional SMN protein, and SMN2, responsible for the production of less protein but sufficient for modifying the SMA phenotype.

Objective: To test whether SMN genotypes are associated with susceptibility to and severity of sporadic ALS.

Methods: We performed competitive quantitative PCR analysis for both SMN1 and SMN2 genes in 242 clinically well-defined ALS patients and 175 controls. The combined determination of SMN1 and SMN2 copies also allowed for an estimation of the level of SMN for each patient (estimated SMN protein level = SMN1 copy number + 0.20 x SMN2 copy number).

Results: One copy of SMN1 was associated with an increased risk of developing ALS (odds ratio = 4.1, 95% CI = 1.2 to 14.2, p = 0.02) and ALS patients carried fewer SMN2 copy numbers (p < 0.001). Sixty-one percent of patients had an estimated protein SMN level ≤2.2 vs only 36% of controls (p = 0.0000004). Multivariate Cox regression analyses showed that lower SMN2 copy numbers and lower levels of estimated SMN protein (hazard ratio = 1.3, 95% CI = 1.1 to 1.6, p = 0.03) were associated with an increased mortality rate.

Conclusions: SMN genotypes producing less SMN protein increase susceptibility to and severity of ALS.


This article was previously published in electronic format as an Expedited E-Pub on August 10, 2005, atwww.neurology.org.

Supported by a grant from the Prinses Beatrix Fonds.

Disclosure: The authors report no conflicts of interest.

Received January 3, 2005. Accepted in final form June 9, 2005.

Please




This article has been cited by other articles:


Home page
Arch NeurolHome page
A. Paubel, J. Violette, M. Amy, J. Praline, V. Meininger, W. Camu, P. Corcia, C. R. Andres, P. Vourc'h, and for the French Amyotrophic Lateral Sclerosis (ALS)
Mutations of the ANG Gene in French Patients With Sporadic Amyotrophic Lateral Sclerosis
Arch Neurol, October 1, 2008; 65(10): 1333 - 1336.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J.C. Schymick, K. Talbot, and B.J. Traynor
Genetics of sporadic amyotrophic lateral sclerosis
Hum. Mol. Genet., October 15, 2007; 16(R2): R233 - R242.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
D. Kasperaviciute, M. E. Weale, K. V. Shianna, G. T. Banks, C. L. Simpson, V. K. Hansen, M. R. Turner, C. E. Shaw, A. Al-Chalabi, H. S. Pall, et al.
Large-scale pathways-based association study in amyotrophic lateral sclerosis
Brain, September 1, 2007; 130(9): 2292 - 2301.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
P. Corcia, W. Camu, J. -M. Halimi, P. Vourc'h, C. Antar, S. Vedrine, B. Giraudeau, B. de Toffol, C. R. Andres, and for The French ALS Study Group
SMN1 gene, but not SMN2, is a risk factor for sporadic ALS
Neurology, October 10, 2006; 67(7): 1147 - 1150.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. E. Shaw and A. Al-Chalabi
Susceptibility genes in sporadic ALS: separating the wheat from the chaff by international collaboration.
Neurology, September 12, 2006; 67(5): 738 - 739.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.